Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018.

Ascierto PA, Butterfield LH, Demaria S, Ferris RL, Freeman GJ, Lo RS, Mantovani A, Nathan P, Hamid O, Politi K, Puzanov I.

J Immunother Cancer. 2019 Aug 15;7(1):221. doi: 10.1186/s40425-019-0683-0. Review.

2.

Prioritizing Chinese Medicine Clinical Research Questions in Cancer Palliative Care: International Delphi Survey.

Wong CHL, Wu IXY, Balneaves LG, Lo RSK, Witt CM, Wu JCY, Leung TH, Chung VCH.

J Pain Symptom Manage. 2019 Aug 9. pii: S0885-3924(19)30443-9. doi: 10.1016/j.jpainsymman.2019.08.002. [Epub ahead of print]

PMID:
31404640
3.

Melanoma to Vitiligo: The Melanocyte in Biology & Medicine-Joint Montagna Symposium on the Biology of Skin/PanAmerican Society for Pigment Cell Research Annual Meeting.

Leachman SA, Hornyak TJ, Barsh G, Bastian BC, Brash DE, Cleaver JE, Cooper CD, D'Orazio JA, Fujita M, Holmen SL, Indra AK, Kraemer KH, Le Poole IC, Lo RS, Lund AW, Manga P, Pavan WJ, Setaluri V, Stemwedel CE, Kulesz-Martin MF.

J Invest Dermatol. 2019 Jul 23. pii: S0022-202X(19)32550-3. doi: 10.1016/j.jid.2019.03.1164. [Epub ahead of print] No abstract available.

PMID:
31348921
4.

Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy).

Ascierto PA, Agarwala SS, Botti G, Budillon A, Davies MA, Dummer R, Ernstoff M, Ferrone S, Formenti S, Gajewski TF, Garbe C, Hamid O, Lo RS, Luke JJ, Michielin O, Palmieri G, Zitvogel L, Marincola FM, Masucci G, Caracò C, Thurin M, Puzanov I.

J Transl Med. 2019 Jul 22;17(1):234. doi: 10.1186/s12967-019-1979-z.

5.

Does an assessment aid improve Glasgow Coma Scale scoring by helicopter rescuers in Hong Kong: A randomised controlled trial.

Chan SY, Tsang CH, Woo WWK, Yeung CY, Leung LY, Lo RSL, Hung KKC, Graham CA.

Australas Emerg Care. 2018 Aug;21(3):105-110. doi: 10.1016/j.auec.2018.06.001. Epub 2018 Jun 25.

PMID:
30998881
6.

Agreement between capillary and venous lactate in emergency department patients: prospective observational study.

Graham CA, Leung LY, Lo RS, Lee KH, Yeung CY, Chan SY, Cattermole GN, Hung KK.

BMJ Open. 2019 Apr 3;9(4):e026109. doi: 10.1136/bmjopen-2018-026109.

7.

Prevalence, Perception, and Predictors of Advance Directives among Hong Kong Chinese: A Population-based Survey.

Chan CWH, Wong MMH, Choi KC, Chan HYL, Chow AYM, Lo RSK, Sham MMK.

Int J Environ Res Public Health. 2019 Jan 28;16(3). pii: E365. doi: 10.3390/ijerph16030365.

8.

The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous Melanoma.

Zhao X, Little P, Hoyle AP, Pegna GJ, Hayward MC, Ivanova A, Parker JS, Marron DL, Soloway MG, Jo H, Salazar AH, Papakonstantinou MP, Bouchard DM, Jefferys SR, Hoadley KA, Ollila DW, Frank JS, Thomas NE, Googe PB, Ezzell AJ, Collichio FA, Lee CB, Earp HS, Sharpless NE, Hugo W, Wilmott JS, Quek C, Waddell N, Johansson PA, Thompson JF, Hayward NK, Mann GJ, Lo RS, Johnson DB, Scolyer RA, Hayes DN, Moschos SJ.

Front Oncol. 2019 Jan 4;8:584. doi: 10.3389/fonc.2018.00584. eCollection 2018.

9.

qSOFA is a Poor Predictor of Short-Term Mortality in All Patients: A Systematic Review of 410,000 Patients.

Lo RSL, Leung LY, Brabrand M, Yeung CY, Chan SY, Lam CCY, Hung KKC, Graham CA.

J Clin Med. 2019 Jan 8;8(1). pii: E61. doi: 10.3390/jcm8010061. Review.

10.

What Patients, Families, Health Professionals and Hospital Volunteers Told Us about Advance Directives.

Chan CWH, Wong MMH, Choi KC, Chan HYL, Chow AYM, Lo RSK, Sham MMK.

Asia Pac J Oncol Nurs. 2019 Jan-Mar;6(1):72-77. doi: 10.4103/apjon.apjon_38_18.

11.

Cross-sectional study on emergency department management of sepsis.

Hung KK, Lam RP, Lo RS, Tenney JW, Yang ML, Tai MC, Graham CA.

Hong Kong Med J. 2018 Dec;24(6):571-578. doi: 10.12809/hkmj177149. Epub 2018 Nov 14.

12.

The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression.

Huang L, Malu S, McKenzie JA, Andrews MC, Talukder AH, Tieu T, Karpinets T, Haymaker C, Forget MA, Williams LJ, Wang Z, Mbofung RM, Wang ZQ, Davis RE, Lo RS, Wargo JA, Davies MA, Bernatchez C, Heffernan T, Amaria RN, Korkut A, Peng W, Roszik J, Lizée G, Woodman SE, Hwu P.

Clin Cancer Res. 2018 Jul 15;24(14):3366-3376. doi: 10.1158/1078-0432.CCR-17-2483. Epub 2018 Mar 1.

13.

Oral paracetamol and/or ibuprofen for treating pain after soft tissue injuries: Single centre double-blind, randomised controlled clinical trial.

Hung KKC, Graham CA, Lo RSL, Leung YK, Leung LY, Man SY, Woo WK, Cattermole GN, Rainer TH.

PLoS One. 2018 Feb 6;13(2):e0192043. doi: 10.1371/journal.pone.0192043. eCollection 2018.

14.

High-Speed Live-Cell Interferometry: A New Method for Quantifying Tumor Drug Resistance and Heterogeneity.

Huang D, Leslie KA, Guest D, Yeshcheulova O, Roy IJ, Piva M, Moriceau G, Zangle TA, Lo RS, Teitell MA, Reed J.

Anal Chem. 2018 Mar 6;90(5):3299-3306. doi: 10.1021/acs.analchem.7b04828. Epub 2018 Feb 13.

PMID:
29381859
15.

Improvement of blood loss volume estimation by paramedics using a pictorial nomogram: A developmental study.

Yeung CY, Yim WW, Chan SY, Lo RSL, Leung LY, Hung KKC, Graham CA.

Injury. 2017 Dec;48(12):2693-2698. doi: 10.1016/j.injury.2017.10.045. Epub 2017 Oct 31.

PMID:
29108791
16.

Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma.

Hong A, Moriceau G, Sun L, Lomeli S, Piva M, Damoiseaux R, Holmen SL, Sharpless NE, Hugo W, Lo RS.

Cancer Discov. 2018 Jan;8(1):74-93. doi: 10.1158/2159-8290.CD-17-0682. Epub 2017 Sep 18.

17.

Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation.

Song C, Piva M, Sun L, Hong A, Moriceau G, Kong X, Zhang H, Lomeli S, Qian J, Yu CC, Damoiseaux R, Kelley MC, Dahlman KB, Scumpia PO, Sosman JA, Johnson DB, Ribas A, Hugo W, Lo RS.

Cancer Discov. 2017 Nov;7(11):1248-1265. doi: 10.1158/2159-8290.CD-17-0401. Epub 2017 Sep 1.

18.

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.

Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA, Zaretsky JM, Sun L, Hugo W, Wang X, Parisi G, Saus CP, Torrejon DY, Graeber TG, Comin-Anduix B, Hu-Lieskovan S, Damoiseaux R, Lo RS, Ribas A.

Cell Rep. 2017 May 9;19(6):1189-1201. doi: 10.1016/j.celrep.2017.04.031.

19.

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.

Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, Seja E, Lomeli S, Kong X, Kelley MC, Sosman JA, Johnson DB, Ribas A, Lo RS.

Cell. 2017 Jan 26;168(3):542. doi: 10.1016/j.cell.2017.01.010. No abstract available.

20.

Outcomes in emergency care research.

Hung KK, Lo RS, Graham CA.

Eur J Emerg Med. 2017 Feb;24(1):1. No abstract available.

PMID:
27984368
21.

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.

Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, Grasso CS, Hugo W, Sandoval S, Torrejon DY, Palaskas N, Rodriguez GA, Parisi G, Azhdam A, Chmielowski B, Cherry G, Seja E, Berent-Maoz B, Shintaku IP, Le DT, Pardoll DM, Diaz LA Jr, Tumeh PC, Graeber TG, Lo RS, Comin-Anduix B, Ribas A.

Cancer Discov. 2017 Feb;7(2):188-201. doi: 10.1158/2159-8290.CD-16-1223. Epub 2016 Nov 30.

22.

Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.

Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2016 Nov 15;14(1):313.

23.

JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma.

Titz B, Lomova A, Le A, Hugo W, Kong X, Ten Hoeve J, Friedman M, Shi H, Moriceau G, Song C, Hong A, Atefi M, Li R, Komisopoulou E, Ribas A, Lo RS, Graeber TG.

Cell Discov. 2016 Sep 6;2:16028. doi: 10.1038/celldisc.2016.28. eCollection 2016.

24.

Regional glutamine deficiency in tumours promotes dedifferentiation through inhibition of histone demethylation.

Pan M, Reid MA, Lowman XH, Kulkarni RP, Tran TQ, Liu X, Yang Y, Hernandez-Davies JE, Rosales KK, Li H, Hugo W, Song C, Xu X, Schones DE, Ann DK, Gradinaru V, Lo RS, Locasale JW, Kong M.

Nat Cell Biol. 2016 Oct;18(10):1090-101. doi: 10.1038/ncb3410. Epub 2016 Sep 12.

25.

Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors.

Escuin-Ordinas H, Li S, Xie MW, Sun L, Hugo W, Huang RR, Jiao J, de-Faria FM, Realegeno S, Krystofinski P, Azhdam A, Komenan SM, Atefi M, Comin-Anduix B, Pellegrini M, Cochran AJ, Modlin RL, Herschman HR, Lo RS, McBride WH, Segura T, Ribas A.

Nat Commun. 2016 Aug 1;7:12348. doi: 10.1038/ncomms12348.

26.

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.

Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, Saco J, Homet Moreno B, Mezzadra R, Chmielowski B, Ruchalski K, Shintaku IP, Sanchez PJ, Puig-Saus C, Cherry G, Seja E, Kong X, Pang J, Berent-Maoz B, Comin-Anduix B, Graeber TG, Tumeh PC, Schumacher TN, Lo RS, Ribas A.

N Engl J Med. 2016 Sep 1;375(9):819-29. doi: 10.1056/NEJMoa1604958. Epub 2016 Jul 13.

27.

Corrigendum: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance.

Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkov AV, Meeth K, Tang HY, Yin X, Wood WH, Lehrmann E, Becker KG, Flaherty KT, Frederick DT, Wargo JA, Cooper ZA, Tetzlaff MT, Hudgens C, Aird KM, Zhang R, Xu X, Liu Q, Bartlett E, Karakousis G, Eroglu Z, Lo RS, Chan M, Menzies AM, Long GV, Johnson DB, Sosman J, Schilling B, Schadendorf D, Speicher DW, Bosenberg M, Ribas A, Weeraratna AT.

Nature. 2016 Sep 8;537(7619):254. doi: 10.1038/nature18939. Epub 2016 Jul 6. No abstract available.

PMID:
27383789
28.

Sepsis - where are the emergency physicians?

Lo RS, Brabrand M, Kurland L, Graham CA.

Eur J Emerg Med. 2016 Jun;23(3):159. doi: 10.1097/MEJ.0000000000000403. No abstract available.

PMID:
27111247
29.

The state of melanoma: challenges and opportunities.

Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA, Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, Atkins MB, Bosenberg MW, Dummer R, Gershenwald JE, Halpern AC, Herlyn D, Karakousis GC, Kirkwood JM, Krauthammer M, Lo RS, Long GV, McArthur G, Ribas A, Schuchter L, Sosman JA, Smalley KS, Steeg P, Thomas NE, Tsao H, Tueting T, Weeraratna A, Xu G, Lomax R, Martin A, Silverstein S, Turnham T, Ronai ZA.

Pigment Cell Melanoma Res. 2016 Jul;29(4):404-16. doi: 10.1111/pcmr.12475. Epub 2016 Apr 17.

30.

sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance.

Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH 3rd, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkov AV, Meeth K, Tang HY, Yin X, Wood WH 3rd, Lehrmann E, Becker KG, Flaherty KT, Frederick DT, Wargo JA, Cooper ZA, Tetzlaff MT, Hudgens C, Aird KM, Zhang R, Xu X, Liu Q, Bartlett E, Karakousis G, Eroglu Z, Lo RS, Chan M, Menzies AM, Long GV, Johnson DB, Sosman J, Schilling B, Schadendorf D, Speicher DW, Bosenberg M, Ribas A, Weeraratna AT.

Nature. 2016 Apr 14;532(7598):250-4. doi: 10.1038/nature17392. Epub 2016 Apr 4.

31.

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.

Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, Seja E, Lomeli S, Kong X, Kelley MC, Sosman JA, Johnson DB, Ribas A, Lo RS.

Cell. 2016 Mar 24;165(1):35-44. doi: 10.1016/j.cell.2016.02.065. Epub 2016 Mar 17. Erratum in: Cell. 2017 Jan 26;168(3):542.

32.

Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms.

Johnson DB, Menzies AM, Zimmer L, Eroglu Z, Ye F, Zhao S, Rizos H, Sucker A, Scolyer RA, Gutzmer R, Gogas H, Kefford RF, Thompson JF, Becker JC, Berking C, Egberts F, Loquai C, Goldinger SM, Pupo GM, Hugo W, Kong X, Garraway LA, Sosman JA, Ribas A, Lo RS, Long GV, Schadendorf D.

Eur J Cancer. 2015 Dec;51(18):2792-9. doi: 10.1016/j.ejca.2015.08.022. Epub 2015 Nov 19.

33.

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance.

Hugo W, Shi H, Sun L, Piva M, Song C, Kong X, Moriceau G, Hong A, Dahlman KB, Johnson DB, Sosman JA, Ribas A, Lo RS.

Cell. 2015 Sep 10;162(6):1271-85. doi: 10.1016/j.cell.2015.07.061.

34.

Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination.

Sanborn JZ, Chung J, Purdom E, Wang NJ, Kakavand H, Wilmott JS, Butler T, Thompson JF, Mann GJ, Haydu LE, Saw RP, Busam KJ, Lo RS, Collisson EA, Hur JS, Spellman PT, Cleaver JE, Gray JW, Huh N, Murali R, Scolyer RA, Bastian BC, Cho RJ.

Proc Natl Acad Sci U S A. 2015 Sep 1;112(35):10995-1000. doi: 10.1073/pnas.1508074112. Epub 2015 Aug 18.

35.

Vemurafenib resistance reprograms melanoma cells towards glutamine dependence.

Hernandez-Davies JE, Tran TQ, Reid MA, Rosales KR, Lowman XH, Pan M, Moriceau G, Yang Y, Wu J, Lo RS, Kong M.

J Transl Med. 2015 Jul 3;13:210. doi: 10.1186/s12967-015-0581-2.

36.

Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma.

Wong DJ, Robert L, Atefi MS, Lassen A, Avarappatt G, Cerniglia M, Avramis E, Tsoi J, Foulad D, Graeber TG, Comin-Anduix B, Samatar A, Lo RS, Ribas A.

Mol Cancer. 2015 Jul 2;14:128. doi: 10.1186/s12943-015-0393-2. No abstract available.

37.

Therapy-induced tumour secretomes promote resistance and tumour progression.

Obenauf AC, Zou Y, Ji AL, Vanharanta S, Shu W, Shi H, Kong X, Bosenberg MC, Wiesner T, Rosen N, Lo RS, Massagué J.

Nature. 2015 Apr 16;520(7547):368-72. doi: 10.1038/nature14336. Epub 2015 Mar 25.

38.

A tetO Toolkit To Alter Expression of Genes in Saccharomyces cerevisiae.

Cuperus JT, Lo RS, Shumaker L, Proctor J, Fields S.

ACS Synth Biol. 2015 Jul 17;4(7):842-52. doi: 10.1021/sb500363y. Epub 2015 Mar 17.

39.

Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.

Moriceau G, Hugo W, Hong A, Shi H, Kong X, Yu CC, Koya RC, Samatar AA, Khanlou N, Braun J, Ruchalski K, Seifert H, Larkin J, Dahlman KB, Johnson DB, Algazi A, Sosman JA, Ribas A, Lo RS.

Cancer Cell. 2015 Feb 9;27(2):240-56. doi: 10.1016/j.ccell.2014.11.018. Epub 2015 Jan 15.

40.

Massively parallel single-amino-acid mutagenesis.

Kitzman JO, Starita LM, Lo RS, Fields S, Shendure J.

Nat Methods. 2015 Mar;12(3):203-6, 4 p following 206. doi: 10.1038/nmeth.3223. Epub 2015 Jan 5.

41.

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.

Müller J, Krijgsman O, Tsoi J, Robert L, Hugo W, Song C, Kong X, Possik PA, Cornelissen-Steijger PD, Geukes Foppen MH, Kemper K, Goding CR, McDermott U, Blank C, Haanen J, Graeber TG, Ribas A, Lo RS, Peeper DS.

Nat Commun. 2014 Dec 15;5:5712. doi: 10.1038/ncomms6712.

42.

Is there a role for probiotics in liver disease?

Lo RS, Austin AS, Freeman JG.

ScientificWorldJournal. 2014;2014:874768. doi: 10.1155/2014/874768. Epub 2014 Nov 11. Review.

43.

Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma.

Wong DJ, Robert L, Atefi MS, Lassen A, Avarappatt G, Cerniglia M, Avramis E, Tsoi J, Foulad D, Graeber TG, Comin-Anduix B, Samatar A, Lo RS, Ribas A.

Mol Cancer. 2014 Aug 20;13:194. doi: 10.1186/1476-4598-13-194. Erratum in: Mol Cancer. 2015;14:128.

44.

Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors.

Marusiak AA, Edwards ZC, Hugo W, Trotter EW, Girotti MR, Stephenson NL, Kong X, Gartside MG, Fawdar S, Hudson A, Breitwieser W, Hayward NK, Marais R, Lo RS, Brognard J.

Nat Commun. 2014 May 22;5:3901. doi: 10.1038/ncomms4901.

45.

Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis.

Parmenter TJ, Kleinschmidt M, Kinross KM, Bond ST, Li J, Kaadige MR, Rao A, Sheppard KE, Hugo W, Pupo GM, Pearson RB, McGee SL, Long GV, Scolyer RA, Rizos H, Lo RS, Cullinane C, Ayer DE, Ribas A, Johnstone RW, Hicks RJ, McArthur GA.

Cancer Discov. 2014 Apr;4(4):423-33. doi: 10.1158/2159-8290.CD-13-0440. Epub 2014 Jan 27.

46.

COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors.

Escuin-Ordinas H, Atefi M, Fu Y, Cass A, Ng C, Huang RR, Yashar S, Comin-Anduix B, Avramis E, Cochran AJ, Marais R, Lo RS, Graeber TG, Herschman HR, Ribas A.

Mol Oncol. 2014 Mar;8(2):250-60. doi: 10.1016/j.molonc.2013.11.005. Epub 2013 Dec 1.

47.

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.

Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, Glaspy JA, Sosman JA, van Baren N, Long GV, Ribas A, Lo RS.

Cancer Discov. 2014 Jan;4(1):80-93. doi: 10.1158/2159-8290.CD-13-0642. Epub 2013 Nov 21.

48.

A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.

Shi H, Hong A, Kong X, Koya RC, Song C, Moriceau G, Hugo W, Yu CC, Ng C, Chodon T, Scolyer RA, Kefford RF, Ribas A, Long GV, Lo RS.

Cancer Discov. 2014 Jan;4(1):69-79. doi: 10.1158/2159-8290.CD-13-0279. Epub 2013 Nov 21.

49.

Detecting mechanisms of acquired BRAF inhibitor resistance in melanoma.

Lo RS, Shi H.

Methods Mol Biol. 2014;1102:163-74. doi: 10.1007/978-1-62703-727-3_10.

PMID:
24258979
50.

Protein interaction analysis of senataxin and the ALS4 L389S mutant yields insights into senataxin post-translational modification and uncovers mutant-specific binding with a brain cytoplasmic RNA-encoded peptide.

Bennett CL, Chen Y, Vignali M, Lo RS, Mason AG, Unal A, Huq Saifee NP, Fields S, La Spada AR.

PLoS One. 2013 Nov 11;8(11):e78837. doi: 10.1371/journal.pone.0078837. eCollection 2013.

Supplemental Content

Support Center